HealthCare Royalty and Blue Owl Capital acquired the target/assets from BridgeBio Pharma in an acquisition.
Deal value was 300000000 Sector: Healthcare; Location: Europe.
On the acquirer side, legal representation details are not available, but involved lawyers include Ryan Murr, Catie Sakurai, Jin Hee Kim, Ryan Kim, Kali Jelen, Jeff Krause, Pamela Endreny, Ryan Rott.
Generated by AI, original source from - Data is in progress
BridgeBio Pharma advisor
Firm name is in progress
Found it useful? Spread the word.
Gibson Dunn advises HealthCare Royalty and Blue Owl Capital on acquisition of BridgeBio Pharma's royalty interest in Bayer's BEYONTTRA® | The Sponsor - The Sponsor
